Pharmaceutical Network November 26th News 2015 is about to pass，The sales of major biopharmaceuticals are still a trend of linear growth，Take a look at these best -selling drugs for billions of billions，or even tens of billions of dollars for sales，I will understand why pharmaceutical companies are spending their strength to develop above，This also directly promotes the continued booming of biopharmaceuticals。

 

 

Biopharmaceutical refers to a class of drugs with biological activity，Biopharmaceuticals can be divided into antibodies、Promoting red blood cells、Promoting follicular hormone、interferon、Gravocytes setting down stimulus factor、growth hormone、Insulin and its analogs、Reorganized coagulation factors and other major categories。

 

 

2015 is about to pass，The sales of major biopharmaceuticals are still a trend of linear growth，Take a look at these best -selling drugs for billions of billions，or even tens of billions of dollars for sales，I will understand why pharmaceutical companies are spending their strength to develop above，This also directly promotes the continued booming of biopharmaceuticals。

 

 

Let ’s comprehensively analyze and predict the top ten best -selling biotechnology in 2016，From the perspective of the attribute, the monoclonal antibody、interferon、Insulin is still the main force。In terms of indication, it is to treat cancer、rheumatoid arthritis、Diabetes and other common chronic diseases are the main。Traditional pharmaceutical giants Roche occupied the top three，But Albervi's Humrira will still lead the lead，Occupy the top chair。

 

 

Data source: Listed company report

 

 

TOP10 AVONEX

 

 

AvoneX is an injectionable & beta; interferon，Its market is very mature，It has unique potions and frozen storage technology，Therefore, the competition with generic drugs has My stake betting appan My stake betting appadvantage，It is still the most sales of Biogen in 2014，The sales in 2014 reached 3 billion US dollars。The patent expired in December 2013，It is bound to be impacted by generic drugs，In the next few years, its sales will continue to decline，It is expected to fall to about $ 1 billion in 2018。But there is news that Biogen Company is in order to stabilize sales，Try to increase the price of the drug，This approach will inevitably cause patients' dissatisfaction，Maybe it is counterproductive。

 

 

TOP9 Nova and Rui NOVORAPID

 

 

Novari is an insulin analogs produced by Novaro，Nuo He Rui compared with ordinary conventional insulin，There are many benefits，Its pharmacological effects can better simulate insulin secretion mode when normal people meals，It is currently the ideal post -meal hyperglycemia control drug，Promoting the method of administration of insulin is more perfect。Its biggest competitor is the Humalog of Lilly。Although this drug patent has expired in June 2014，But its good effect has been accepted by the majority of patients。Biotechnology drugs will not affect its sales in a short period of time，It is expected that the sales volume in the next few years will remain above US $ 3 billion，Not growing up。

 

 

TOP8 Neulasta

 

 

Neulasta is the world's first long-acting RHG-CSF product launched by AMGEN in 2002，It can stimulate the production of white blood cells to reduce the side effects of anti -tumor chemotherapy，Extract the molecular weight of the drug through PEG (polyethylene glycol)，Slow down its clearing rate in the body and effectively extend the half -life of the drug，The frequency of injection administration is reduced from multiple times of each chemotherapy treatment to one time，Reduced the pain caused by frequent injection to patients，and the problem of frequent interruption of treatment due to severe infection disease during chemotherapy，The compliance of patients at the same time is greatly improved。 2002-2014，Neulasta's sales increased from US $ 464 million to $ 4.688 billion，12 years of sales increased by 9 times，Compound annual growth rate of 22.7%。

 

 

Top7 Herceptin

 

 

Roche's Herceptin is the gold standard for treating Her2 positive breast cancer，Its active ingredients are Tuskuzumab is a humanized monoclonal antibody derived from DNA，However, the market has become saturated，The increase in sales has Stake Sports Bettingstake sports betting appbecome slower。Another Perjeta and KADCYLA in Roche have been launched to replace Herceptin ，Used to cope with the competition of biotechnology drugs。A variety of Hercepts of Herception biotechnology threatened Her againstin's sales market，Despite this，It still maintains an annual sales of 6.275 billion in 2014，Competition of generic drugs，Its annual sales will shrink，It is expected that it will fall to $ 5.8 billion in 2016。

 

 

TOP6 when it comes

 

 

Lantus of Sanofi is a long -acting insulin analog，It is mainly used to treat type II diabetes，It competes with Levemir of Pfizer Pharmaceutical，Lilly Lilly also has this medicine biological generic drug，Approved in May 2015，But during the approval of the United States, it caused patented disputes with Sanofi。Affected by this, Lantus sales fell by 5.4%in the third quarter。 Sanofi Company complained that the patient gave the company a lot of price pressure，They have to reduce the price to ensure sales，The effect of this can be seen from the sales performance of the fourth quarter of 2014，Sales growth is higher than 17%，Sales in 2014 reached US $ 6.344 billion。

 

 

TOP5 Avastin

 

 

Avastein is a monoclonal drug，As a drug generated by antibodium，Block the tumor by inhibiting the action of the growth factors of vascular endothelial，Inhibit the spread of tumors in the body，Enhance the treatment efficacy。 In 2011, the FDA declared that the breasts of the United States were different from the European breasts of the United States brought a great vibration to the market，Sales volume fell 18%。There is currently a recovery，It also maintains the status of the main treatment method of European diffuse breast cancer。After being approved by FDA/EU in 11 years，Another good news is that the FDA will recently approve the preferred treatment of uterine and ovarian cancer，Sales in 2014 reached US $ 6.417 billion，With the increase of its indications，It can be predicted that its sales will still stay at the peak for several years。

 

 

TOP4 Meiluo Hua

 

 

Dading Lichel Ming Mingist is the world's first monoclonal antibody drug to treat non -Hodgkin lymphoma cancer，Later, the treatment of multiple lymphoma and blood cancer was later annotated，It is also a second -line drug of rheumatoid arthritis。The good therapeutic effect of Lipchen Ming makes many generic drug companies want to move，Start testing generic drugs。But in fact, the stake betting appstake online sports bettingcompetitors of the Lichell monoclonal anti -anti -resistance come from their own: Roche begins to produce its alternative: Gazyva，Various clinical studies have shown that Gazyva Bilcieccix Mibab has a better curative effect，It is certain that the market space of Lichell monoclonal resistance will be continuously seized by this younger brother。

 

 

TOP3 Enli

 

 

ENBREL is TNF & Alpha; inhibitor，Used to treat rheumatoid arthritis，Psoriasis arthritis and ankylosing joints。Its active ingredients are reorganized human tumor necrotic factor receptors P75 FC fusion protein。Eli Yingyin and Amegen, two companies, sold together， AMGEN takes over its market in the United States，and Pfizer is responsible for buying Enbret outside the United States，The company report shows that their sales in 2014 were 4.69 billion and US $ 3.85 billion。It should be noted that the patent of American dried powder has expired，Pharmacy of water solvent type did not expire until 2023。There are many biotechnology drugs are under development，Including a drug in the advanced test of a Snadoz，and India's CIPLA's generic drugs have been approved。

 

 

TOP2 gram

 

 

Remicade is a treatment of Crohn's disease、rheumatoid arthritis，TNF antibody of psoriasis arthritis。The company once worried that Pfizer's oral new drug Xeljanz will bring threats，But the facts prove that worry is extra。Its main threat comes from generic drugs: The European Pharmaceutical Inspection Agency approves the biotechnology of the REMICADE of Celltrion and Hospira，Name of REMSIMA，Fortunately, these drugs are listed in a small number of European markets that Johnson & Johnson loses patent protection，The effect of the impact of these biological generic drugs can be fully appeared in the coming year 。Generally speaking, Remicade has not been impacted by biotechnology，On the contrary, sales are still rising，It is not even affected by the changes in the supply chain。

 

 

TOP1 Xiu Meile

 

 

The sales champion of biopharmaceuticals in 2014 is HUMIRA，Its sales reached $ 12.5 billion，Two times the second place in the second place in the second place。Humira, also known as Adamab，It can slow down rheumatoid arthritis，Psoriac disease arthritis，and ankylosing spondylitis ，Recently, it applied for a variety of indications such as mid -axis spine arthritis，This medicine can be injected stake sports betting appStake Sports Bettingin the patient's home，Compared to some other drugs that relieve the disease, it is much easier。It is interesting that some so -called human -based antibody competitors, such as Johnson & Johnson's Simponi and UCBA's Cimzia, did not reduce HUMIRA sales，Not to mention the oral Xeljanz of Pfizer。Not to mention the oral Xeljanz of Pfizer，Patent will expire in 2016，It can be imagined that all major generic drug companies around the world have been stared at，Even began to develop its generic drugs。Alber applies for the FDA for this franchise right。In the third quarter of 2014, sales increased by 17%，and the growth momentum is not diminished，The main problem faced now is，How much can the tendency of the growth of this growth，The good news is that the patient does not seem to be resistant to price issues，There is still room for rising prices，It seems that there will be no drugs in the next few years that can threaten the status of its leading boss。